Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease

Biomedical Reports

Volumn 5, Issue 2, 2016, Pages 188-192

  Huang, Qian ^a   Yu, Jianhua ^a   Zhang, Xiantu ^a   Liu, Shourong ^a   Ge, Yanyan ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b THE THIRD PEOPLE S HOSPITAL OF HANGZHOU   (China)

Author keywords

Histology; Inflammation; Non alcoholic fatty liver disease; Uric acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; BENZBROMARONE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; HYPERURICEMIA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; RISK FACTOR; STEATOSIS; URIC ACID BLOOD LEVEL;

EID: 85017444143     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.698     Document Type: Article

References (28)

1. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y and Wasada T: Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22: 1141-1145, 2005.
2. Fan JG and Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50: 204-210, 2009.
3. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ and Goh KL; Asia-Pacific Working Party on NAFLD: How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793, 2007.
4. Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, van der Graaf Y and Visseren F: Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 34: 1882-1887, 2007.
5. Choi HK and Ford ES: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120: 442-447, 2007.
6. Li Y, Xu C, Yu C, Xu L and Miao M: Association of serum uric acid level with non-alcoholic fatty liver disease: A cross-sectional study. J Hepatol 50: 1029-1034, 2009.
7. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M and Jalal DI: Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 62: 392-399, 2013.
8. Lee YJ, Lee HR, Lee JH, Shin YH and Shim JY: Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 48: 175-180, 2010.
9. Xu C, Yu C, Xu L, Miao M and Li Y: High serum uric acid increases the risk for nonalcoholic Fatty liver disease: A prospective observational study. PLoS One 5: e11578, 2010.
10. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, et al: Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. J Biol Chem 287: 40732-40744, 2012.
11. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ and Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60: 1258-1269, 2011.
12. Petta S, Cammà C, Cabibi D, Di Marco V and Craxì A: Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 34: 757-766, 2011.
13. Flegal KM, Carroll MD, Kit BK and Ogden CL: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307: 491-497, 2012.
14. Reynolds K, Gu D, Whelton PK, Wu X, Duan X, Mo J and He J; InterASIA Collaborative Group: Prevalence and risk factors of overweight and obesity in China. Obesity (Silver Spring) 15: 10-18, 2007.
15. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr and Lenfant C; American Heart Association, National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438, 2004.
16. Fang J and Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410, 2000.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al; Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
18. Sautin YY, Nakagawa T, Zharikov S and Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293: C584-C596, 2007.
19. Xu CF, Yu CH, Xu L, Sa XY and Li YM: Hypouricemic therapy: A novel potential therapeutic option for nonalcoholic fatty liver disease. Hepatology 52: 1865-1866, 2010.
20. Crane JK and Mongiardo KM: Pro-inflammatory effects of uric acid in the gastrointestinal tract. Immunol Invest 43: 255-266, 2014.
21. Martinon F: Signaling by ROS drives inflammasome activation. Eur J Immunol 40: 616-619, 2010.
22. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM and Dixit VD: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17: 179-188, 2011.
23. Kim SM, Lee SH, Kim YG, Kim SY, Seo JW, Choi YW, Kim DJ, Jeong KH, Lee TW, Ihm CG, et al: Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 308: F993-F1003, 2015.
24. Iracheta-Vellve A, Petrasek J, Satishchandran A, Gyongyosi B, Saha B, Kodys K, Fitzgerald KA, Kurt-Jones EA and Szabo G: Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol 63: 1147-1155, 2015.
25. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A and Johnson RJ: A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6: 1887-1894, 2011.
26. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, et al: Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 3: 73-81, 2010.
27. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R and Covic A: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39: 1227-1233, 2007.
28. Afzali A, Weiss NS, Boyko EJ and Ioannou GN: Association between serum uric acid level and chronic liver disease in the United States. Hepatology 52: 578-589, 2010.